Qu Fengjiang, Jiang Tinghan, Liu Zhenzhen, Ling Rui, Zhao Yi, Yang Hongjian, Liu Yunjiang, Liu Ke, Zhang Jianguo, Mao Dahua, He Jianjun, Yu Zhigang, Liu Yinhua, Fu Peifen, Wang Jiandong, Jiang Hongchuan, Zhao Zuowei, Tian Xingsong, Cao Zhongwei, Wu Kejin, Song Ailin, Jin Feng, Wu Di, Fan Zhimin
Department of Emergency Surgery, The First Hospital of Jilin University, Changchun, Jilin Province 130021, China.
Ministry of Education, The First Hospital of Jilin University, Changchun, Jilin Province 130021, China.
iScience. 2025 Jun 13;28(7):112889. doi: 10.1016/j.isci.2025.112889. eCollection 2025 Jul 18.
The real-world application of tracers for axillary sentinel lymph node biopsy (SLNB) for breast cancer (BC) after neoadjuvant chemotherapy (NAC) in China was unknown. We analyzed the use of individual tracers or combinations and number of SLNs in patients with BC who underwent SLNB with or without axillary lymph node dissection (ALND) after NAC in 20 hospitals in ten years. A total of 1251 BC patients underwent SLNB or SLNB + ALND after NAC, including 853 (68.2%, 853/1251) with a single tracer, predominantly Methylene blue (MB) (60.1%, 752/1251); and 398 (31.8%, 398/1251) with dual tracers, mainly MB combined with radioisotope (RI) (18.1%, 226/1251).The results showed that the predominance of the MB single-tracer method for SLNB after NAC limits the popularity of SLNB in patients with BC after NAC in China. MB combined with RI is the main dual-tracer method, and detects SLNs more effectively than MB alone.
在中国，新辅助化疗（NAC）后用于乳腺癌（BC）腋窝前哨淋巴结活检（SLNB）的示踪剂在现实世界中的应用情况尚不清楚。我们分析了十年间在20家医院接受NAC后进行SLNB（无论是否进行腋窝淋巴结清扫术[ALND]）的BC患者中，单个示踪剂或其组合的使用情况以及前哨淋巴结的数量。共有1251例BC患者在NAC后接受了SLNB或SLNB + ALND，其中853例（68.2%，853/1251）使用单一示踪剂，主要是亚甲蓝（MB）（60.1%，752/1251）；398例（31.8%，398/1251）使用双示踪剂，主要是MB与放射性同位素（RI）联合使用（18.1%，226/1251）。结果表明，NAC后SLNB采用MB单示踪剂方法占主导地位，这限制了SLNB在中国NAC后BC患者中的普及。MB与RI联合是主要的双示踪剂方法，且比单独使用MB能更有效地检测前哨淋巴结。
